• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Is India Ready For Phase I Studies?

Is India Ready For Phase I Studies?

August 15, 2006
CenterWatch Staff

India has come a long way as a center for clinical drug trials, but is the country ready for Phase I studies? I think the short answer - and others would agree - is “no”. Take, for instance, recent comments by Ashwini Kumar, the Drug Controller General of India (DCGI), who spoke recently at the Drug Information Association’s (DIA) Annual Meeting in Philadelphia. Kumar, head of the Central Drug Standard Control Organization (CDSCO), India’s regulatory agency, said that India needed to create an environment for the best quality assurance before embarking on phase I studies...

As a first step, the country upgraded regulations governing clinical research - Schedule Y - last year to harmonize them with U.S. and international standards. It also eliminated “phase lag,” which mandated that India not begin a phase of a global trial program until that phase had been completed elsewhere.

The new regulations gave rise to expectations that India would begin to allow first-in-man studies. No dice. India still forbids Phase I studies unless the molecule was developed there. India basically is a Phase II/III market, and “Phase I” in the Indian context generally means bioequivalence & bioavailability studies, which are less complex to run and yield less informative data than first-in-man studies.

But biopharmaceutical companies can get around Phase I barriers by doing that portion of the study outside the country and completing the rest in India. Some contract research organizations (CROs) are already doing this. A CRO will bring an entire project management team from the West after conducting a first-in-man study outside India. That’s not the norm, though, as the logistics can be difficult.

For now, this doesn’t mean that domestic pharma has a real edge over Western pharma. But large, formerly generic, Indian pharma companies are beginning to invest in new drug development and can develop a molecule for which they are able to conduct preclinical studies through phase III in India without the kind of interruption and limitations that Western companies experience.

Discussions about creating a more FDA-like regulatory body in India are ongoing, and that would certainly be another significant step toward creating confidence in hosting first-in-man studies and also toward making the country a truly global player in the clinical research market.

    Upcoming Events

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing